Page 1

NEWBURY Interim report Sep 2021- Nov 2021 Newbury Pharmaceuticals AB Interim report September 2021 - November 2021 Quarter 1 , September 2021 - November 2021 • • Operating cash flow was -4 744 ( -49 ) tkr . Cash position in the end of period was 7682 ( 51 ) tkr . Licensed products in the end of period were 25 . • Products with marketing authorization in the end of the period were 1 . Events during the quarter • • The management was strengthened with CEO Lars Minor and CFO Christoffer Tell . Enlargement of the portfolio with additional seven ( 7 ) oncology products ; Nintedanib , Palbociclib , Pomalidomide , Nilotinib , Enzalutamide , Lenvatinib , Bosutinib . Events after the end of the quarter • • Enlargement of the oncology portfolio with the addition of Lapatinib . Agreement on an exclusive license to commercialize its own brand of Teduglutide 5mg pre- filled syringe in the Nordics . SEK thousands Q1 Sep 21 - Nov 21 Q1 Full year Sep 20 - Nov 20 Sep 20 - Aug 21 Net revenue 0 0 2829 Operating result / EBIT -3 781 -192 -5 621 Result before tax -3 740 -192 -5 557 Cash flow from operating activities -4 744 -49 -4.066 Cash at the end of the period 7 682 51 13 145 Newbury Pharmaceuticals AB 1